© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 4, 338-344,
February 16, 2000
© 2000 Oxford University Press
REPORTS |
Restored Expression of Fragile Histidine Triad Protein and Tumorigenicity of Cervical Carcinoma Cells
Affiliations of authors: R. Wu, D. C. Connolly, K. R. Cho, Departments of Pathology and Internal Medicine, The University of Michigan Medical School, Ann Arbor; R. L. Dunn, Biostatistics Core, University of Michigan Comprehensive Cancer Center, Ann Arbor.
Correspondence to: Kathleen R. Cho, M.D., Department of Pathology, The University of Michigan Medical School, 4301 MSRBIII, 1150 W. Medical Center Dr., Ann Arbor, MI 48109 (e-mail: kathcho{at} umich.edu).
BACKGROUND: Allelic losses in the short arm of chromosome 3 are common in cervical carcinomas. The fragile histidine triad (FHIT) gene at chromosome region 3p14.2 is a candidate tumor suppressor gene that may play a role in cervical tumorigenesis. We and others have identified aberrant FHIT transcripts and frequent loss of Fhit protein expression in primary cervical cancers and high-grade noninvasive lesions but not in normal cervical tissues. The altered expression of FHIT may be due to somatic mutations or integration of human papillomavirus DNA at the FHIT locus. The purpose of this study was to determine whether ectopic expression of Fhit can suppress the tumorigenic properties of cervical cancer cells. METHODS: We employed infection with recombinant retroviruses as well as transfection of plasmid DNA to restore Fhit protein expression in cervical cancer cell lines lacking full-length FHIT transcripts and endogenous Fhit protein. The effects of Fhit expression on tumor cell morphology, anchorage-independent growth, and tumorigenicity in nude mice were examined. RESULTS: Stable overexpression of Fhit had no discernible effect on the tumorigenic properties of two cervical carcinoma cell lines or on a lung carcinoma cell line previously reported by others to be suppressed for tumorigenicity by Fhit. CONCLUSIONS: Restoration of Fhit expression does not suppress anchorage-independent growth or tumorigenicity of cervical carcinoma cell lines. However, it remains possible that FHIT inactivation may be important early in cervical tumor progression or that FHIT may suppress tumorigenesis in ways distinct from those measured by the assays employed in this study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Ratto, R. Ricci, V. Valentini, F. Castri, A. Parello, M. A. Gambacorta, N. Cellini, F. M. Vecchio, and G. B. Doglietto Neoplastic Mesorectal Microfoci (MMF) following Neoadjuvant Chemoradiotherapy: Clinical and Prognostic Implications Ann. Surg. Oncol., February 1, 2007; 14(2): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ratto, R. Ricci, V. Valentini, F. Castri, A. Parello, M. A. Gambacorta, N. Cellini, F. M. Vecchio, and G. B. Doglietto Neoplastic Mesorectal Microfoci (MMF) Following Neoadjuvant Chemoradiotherapy: Clinical and Prognostic Implications Ann. Surg. Oncol., November 1, 2006; 13(11): 1393 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Schwartz, S. L. R. Kardia, K. A. Shedden, R. Kuick, G. Michailidis, J. M. G. Taylor, D. E. Misek, R. Wu, Y. Zhai, D. M. Darrah, et al. Gene Expression in Ovarian Cancer Reflects Both Morphology and Biological Behavior, Distinguishing Clear Cell from Other Poor-Prognosis Ovarian Carcinomas Cancer Res., August 15, 2002; 62(16): 4722 - 4729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines PNAS, March 19, 2002; 99(6): 3615 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kraggerud, P. Aman, R. Holm, A. E. Stenwig, S. D. Fossa, J. M. Nesland, and R. A. Lothe Alterations of the Fragile Histidine Triad Gene, FHIT, and Its Encoded Products Contribute to Testicular Germ Cell Tumorigenesis Cancer Res., January 1, 2002; 62(2): 512 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Krivak, J. W. McBroom, J. Seidman, D. Venzon, B. Crothers, P. J. MacKoul, G. S. Rose, J. W. Carlson, and M. J. Birrer Abnormal Fragile Histidine Triad (FHIT) Expression in Advanced Cervical Carcinoma: A Poor Prognostic Factor Cancer Res., June 1, 2001; 61(11): 4382 - 4385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ishii, K. R. Dumon, A. Vecchione, F. Trapasso, K. Mimori, H. Alder, M. Mori, G. Sozzi, R. Baffa, K. Huebner, et al. Effect of Adenoviral Transduction of the Fragile Histidine Triad Gene into Esophageal Cancer Cells Cancer Res., February 1, 2001; 61(4): 1578 - 1584. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. C. Connolly, D. L. Greenspan, R. Wu, X. Ren, R. L. Dunn, K. V. Shah, R. W. Jones, F. X. Bosch, N. Muñoz, and K. R. Cho Loss of Fhit Expression in Invasive Cervical Carcinomas and Intraepithelial Lesions Associated with Invasive Disease Clin. Cancer Res., September 1, 2000; 6(9): 3505 - 3510. [Abstract] [Full Text]
|
|
|
|
|
|
N. S. Werner, Z. Siprashvili, L. Y. Y. Fong, G. Marquitan, J. K. Schroder, W. Bardenheuer, S. Seeber, K. Huebner, J. Schutte, and B. Opalka Differential Susceptibility of Renal Carcinoma Cell Lines to Tumor Suppression by Exogenous Fhit Expression Cancer Res., June 1, 2000; 60(11): 2780 - 2785. [Abstract] [Full Text]
|
|